Anti-TNF alpha antibodies which selectively inhibit TNF alpha signalling through the p55R
US9840556B2 · kind B2 · utility
1Cited by
5References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 24, 2005 |
| Grant date | Dec 12, 2017 |
| Priority date | — |
| Expiry date | Nov 28, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides anti-TNFα antibodies which selectively inhibit TNFα signalling through the p55R. In particular the present invention provides anti-TNFα antibodies which selectively inhibit TNFα signalling through the p55R relative to the p75R.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.